BRCA mutation status

December 4, 2019

Rubraca Reimbursement Approved in Italy for Women With Relapsed Platinum-sensitive Ovarian Cancer

News

The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, ... Read more

October 30, 2019October 30, 2019

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

News

Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase ... Read more

January 30, 2019

Rubraca Maintenance Approved in Europe for Relapsed Ovarian Cancer

News

The European Commission has extended Rubraca‘s (rucaparib) approval as a maintenance therapy for women with advanced, relapsed ovarian cancer who are in complete or partial response to platinum-based chemotherapy. This recent ... Read more

May 11, 2018

Lynparza Tablets Approved in EU to Treat Advanced, Platinum-sensitive Ovarian Cancers

News

The European Medicines Agency (EMA) has approved Lynparza (olaparib) tablets as a maintenance therapy for ovarian cancer patient who have relapsed, but have had a complete or partial response to platinum-based chemotherapy, and ... Read more

October 12, 2016October 31, 2016

Niraparib Maintenance Treatment Significantly Increased Outcomes for Ovarian Cancer Patients

News

Ovarian cancer patients with recurrent, platinum-sensitive disease may benefit greatly from niraparib maintenance treatment, according to data from a Phase 3 trial in which niraparib significantly prolonged patients’ progression-free survival compared ... Read more